{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-012871","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.277863+00:00","generated_at":"2026-06-24T01:49:56.278594+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Omeros reports Q2 2022 net loss $30.9M; narsoplimab FDA dispute decision expected August","bullets":["Royalties of $17.2M on OMIDRIA sales of $34.5M, a new all-time high.","Net loss $30.9M ($0.49/share) vs $28.6M ($0.46/share) in Q2 2021.","Cash and short-term investments $122.6M as of June 30, down $19.7M from Q1.","Submitted Formal Dispute Resolution to FDA for narsoplimab in TA-TMA; decision expected in August 2022.","OMS906 received orphan drug designation for PNH; Phase 1b trials expanding to treatment-naïve and C3G patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-012871","json":"https://secwatch.observer/filing/0001558370-22-012871.json","markdown":"https://secwatch.observer/filing/0001558370-22-012871.md","text":"https://secwatch.observer/filing/0001558370-22-012871.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000155837022012871/0001558370-22-012871-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000155837022012871/omer-20220809x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:49:56.278594+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}